Evaluation of Gadoterate in Patients With Renal Dysfunction

PHASE4TerminatedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

November 5, 2014

Primary Completion Date

March 20, 2024

Study Completion Date

March 20, 2024

Conditions
Renal Dysfunction
Interventions
DRUG

Gadoterate

Patients who choose to receive Gadoterate will receive an MRI exam with standard pre-contrast and Gadoterate-enhanced acquisitions (0.2 mL/kg). The MRI protocol utilized in the study will be comprised of the standard Body protocols (routine abdomen, liver-pancreas, renal, prostate, angiography) as well as the standard Neurologic exam protocols (routine brain, orbital, brainstem, neck, angiography).

OTHER

No Gadoterate

Patients who choose not to receive Gadoterate will receive an MRI exam with no Gadolinium contrast. The MRI protocol utilized in the study will be comprised of the standard Body protocols (routine abdomen, liver-pancreas, renal, prostate, angiography) as well as the standard Neurologic exam protocols (routine brain, orbital, brainstem, neck, angiography).

Trial Locations (1)

60153

Loyola University Medical Center, Maywood

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Guerbet

INDUSTRY

lead

Loyola University

OTHER